The Claim
In patients with established atherosclerosis who are already receiving statin therapy, treatment with evolocumab does not significantly increase the risk of hemorrhagic stroke compared to placebo, as demonstrated by a hazard ratio of 1.16 (95% confidence interval: 0.68–1.98) and a p-value of 0.59, indicating no statistically significant difference in the incidence of brain bleeding events between groups.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with hardened arteries who are on cholesterol-lowering drugs, adding a drug called evolocumab doesn’t seem to raise their risk of bleeding in the brain.
See the scientific wording
In patients with established atherosclerosis on statin therapy, evolocumab does not increase the risk of hemorrhagic stroke, with no statistically significant difference observed between treatment and placebo groups (0.21% vs 0.18%; hazard ratio, 1.16 [95% CI, 0.68–1.98]; P = 0.59), suggesting a favorable safety profile regarding bleeding events in the brain.
What the research says
1 studyThe study looked at whether a drug called evolocumab causes more brain bleeds in patients already on statins, and found no increased risk compared to placebo.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.